Valion Bio, Inc. Common Stock (VBIO) Competitors

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to Lifeward's net margin of -90.38%. Valion Bio, Inc. Common Stock's return on equity of -109.83% beat Lifeward's return on equity.

Lifeward currently has a consensus price target of $10.00, indicating a potential upside of 42.86%. Given Lifeward's stronger consensus rating and higher probable upside, equities research analysts clearly believe Lifeward is more favorable than Valion Bio, Inc. Common Stock.

Lifeward has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500.

Valion Bio, Inc. Common Stock has lower revenue, but higher earnings than Lifeward.

In the previous week, Lifeward and Lifeward both had 1 articles in the media. Lifeward's average media sentiment score of 0.00 equaled Valion Bio, Inc. Common Stock'saverage media sentiment score.

26.8% of Lifeward shares are owned by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. 1.5% of Lifeward shares are owned by insiders. Comparatively, 2.4% of Valion Bio, Inc. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valion Bio, Inc. Common Stock's return on equity of -109.83% beat Modular Medical's return on equity.

Valion Bio, Inc. Common Stock has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500. Comparatively, Modular Medical has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500.

Valion Bio, Inc. Common Stock has higher revenue and earnings than Modular Medical.

In the previous week, Modular Medical had 2 more articles in the media than Valion Bio, Inc. Common Stock. MarketBeat recorded 3 mentions for Modular Medical and 1 mentions for Valion Bio, Inc. Common Stock. Modular Medical's average media sentiment score of 0.39 beat Valion Bio, Inc. Common Stock's score of 0.00 indicating that Modular Medical is being referred to more favorably in the news media.

4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. Comparatively, 27.5% of Modular Medical shares are owned by institutional investors. 2.4% of Valion Bio, Inc. Common Stock shares are owned by insiders. Comparatively, 7.1% of Modular Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valion Bio, Inc. Common Stock has higher revenue and earnings than Quoin Pharmaceuticals.

In the previous week, Quoin Pharmaceuticals and Quoin Pharmaceuticals both had 1 articles in the media. Quoin Pharmaceuticals' average media sentiment score of 0.00 equaled Valion Bio, Inc. Common Stock'saverage media sentiment score.

Quoin Pharmaceuticals has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500.

Valion Bio, Inc. Common Stock's return on equity of -109.83% beat Quoin Pharmaceuticals' return on equity.

8.6% of Quoin Pharmaceuticals shares are held by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. 13.5% of Quoin Pharmaceuticals shares are held by company insiders. Comparatively, 2.4% of Valion Bio, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Check-Cap has higher earnings, but lower revenue than Valion Bio, Inc. Common Stock.

In the previous week, Check-Cap and Check-Cap both had 1 articles in the media. Check-Cap's average media sentiment score of 0.00 equaled Valion Bio, Inc. Common Stock'saverage media sentiment score.

Check-Cap has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500.

Check-Cap's return on equity of 0.00% beat Valion Bio, Inc. Common Stock's return on equity.

1.1% of Check-Cap shares are held by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. 0.5% of Check-Cap shares are held by company insiders. Comparatively, 2.4% of Valion Bio, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.